Fig. 3.

Experimental validation of KAR prediction of FGFR1 and mTOR dependence for lung cancer cell line H1581. (A) 10 nm ponatinib (FGFR inhibitor) and AZD8055 (mTOR inhibitor) were applied to H1581 cells and cell proliferation was measured with the CYQUANT assay kit. The combination of ponatinib and AZD8055 was synergistic by Bliss Independence (Additive prediction = 19.4%, Actual = 6.7%). Bar graphs display mean percent of control (POC) +/− SEM (B) Western blots showing changes in signaling with ponatinib, AZD8055, and the combo. Ponatinib decreases ERK1/2 activation and AZD8055 decreases signaling downstream of mTOR. (C) Signaling network diagram for pathways targeted by ponatinib and AZD8055 in H1581